• Ambry Genetics-Led Research Collaboration Clears Path to Understanding Optic Atrophy in Mitochondrial Disease
  • GenSight Biologics Reports GS010 Has Promise for Improving Long-term Vision in LHON Patients
  • NeuroVive Selects Compound from NVP015 Program for Preclinical Studies in Mitochondrial Disorders
  • FDA Grants Stealth Fast Track Designation for Elamipretide in Barth Syndrome
  • Preliminary Results of Phase 2 Trial Show Khondrion’s KH176 Safe for Treating Mitochondrial Disease
  • Low Coenzyme Q Is Common Among Genetic Models of Mitochondrial Dysfunction, Study Finds
  • Rare Disease Patient Groups Unite to Preserve Orphan Drug Tax Credit in US
  • Patent Likely to Be Issued to Mitochon for Mitochondria-targeted Therapies
  • Migraine, Tension-Type Headaches Common in Mitochondrial Patients, Study Shows
  • NeuroVive Gets Signal That EU Will Give Its Mitochondrial Therapy KL1333 Orphan Drug Status
  • Khondrion’s Lead Candidate Therapy for Mitochondrial Disease Wins New Patents
  • Preclinical Studies Show MA-0217 Has Potential to Improve Mitochondria Activity, Kidney Function